Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH.

PubWeight™: 3.24‹?› | Rank: Top 1%

🔗 View Article (PMID 12853198)

Published in Lancet on July 05, 2003

Authors

Julian R Sampson1, Sunil Dolwani, Sian Jones, Diana Eccles, Anthony Ellis, D Gareth Evans, Ian Frayling, Sheila Jordan, Eamonn R Maher, Tony Mak, Julie Maynard, Francesca Pigatto, Joan Shaw, Jeremy P Cheadle

Author Affiliations

1: Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff, UK. sampson@cardiff.ac.uk

Articles citing this

Base-excision repair of oxidative DNA damage. Nature (2007) 5.44

Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology (2008) 5.19

ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol (2015) 3.19

Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet (2005) 2.17

Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology (2008) 1.69

Survival of MUTYH-associated polyposis patients with colorectal cancer and matched control colorectal cancer patients. J Natl Cancer Inst (2010) 1.48

Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer (2005) 1.40

The genetics of FAP and FAP-like syndromes. Fam Cancer (2006) 1.34

Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA (2012) 1.31

Germline mutations of the MYH gene in Korean patients with multiple colorectal adenomas. Int J Colorectal Dis (2007) 1.23

Functional characterization of two human MutY homolog (hMYH) missense mutations (R227W and V232F) that lie within the putative hMSH6 binding domain and are associated with hMYH polyposis. Nucleic Acids Res (2005) 1.21

Characterization of mutant MUTYH proteins associated with familial colorectal cancer. Gastroenterology (2008) 1.18

Familial adenomatous polyposis: experience from a study of 1164 unrelated german polyposis patients. Hered Cancer Clin Pract (2005) 1.13

Colonic polyps in children and adolescents. Can J Gastroenterol (2007) 1.12

A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer (2010) 1.11

MUTYH Associated Polyposis (MAP). Curr Genomics (2008) 1.06

The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer (2006) 1.06

A structural hinge in eukaryotic MutY homologues mediates catalytic activity and Rad9-Rad1-Hus1 checkpoint complex interactions. J Mol Biol (2010) 1.04

Colonic adenomatous polyposis syndromes: clinical management. Clin Colon Rectal Surg (2008) 1.02

Intraductal papillary mucinous neoplasm of the pancreas in a patient with attenuated familial adenomatous polyposis. J Clin Pathol (2005) 1.02

Adenine removal activity and bacterial complementation with the human MutY homologue (MUTYH) and Y165C, G382D, P391L and Q324R variants associated with colorectal cancer. DNA Repair (Amst) (2009) 1.00

The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. Dtsch Arztebl Int (2010) 0.99

Investigation of pathogenic mechanisms in multiple colorectal adenoma patients without germline APC or MYH/MUTYH mutations. Br J Cancer (2007) 0.99

Physical and functional interactions between Escherichia coli MutY glycosylase and mismatch repair protein MutS. J Bacteriol (2006) 0.99

Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. Br J Cancer (2004) 0.97

Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer (2011) 0.97

Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol (2014) 0.96

Functional characterization of human MutY homolog (hMYH) missense mutation (R231L) that is linked with hMYH-associated polyposis. Cancer Lett (2006) 0.96

Antimutator role of DNA glycosylase MutY in pathogenic Neisseria species. J Bacteriol (2005) 0.94

Recently identified colon cancer predispositions: MYH and MSH6 mutations. Semin Oncol (2007) 0.94

Pathological features of colorectal carcinomas in MYH-associated polyposis. Histopathology (2008) 0.94

Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients. Hum Genet (2004) 0.90

The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance. Hered Cancer Clin Pract (2005) 0.90

Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant proteins found in patients with colorectal polyposis and cancer. Hum Mutat (2010) 0.90

Identification and characterization of two forms of mouse MUTYH proteins encoded by alternatively spliced transcripts. Nucleic Acids Res (2004) 0.90

The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet (2015) 0.89

Mammalian MutY homolog (MYH or MUTYH) protects cells from oxidative DNA damage. DNA Repair (Amst) (2013) 0.88

Mutational spectrum of the APC and MUTYH genes and genotype-phenotype correlations in Brazilian FAP, AFAP, and MAP patients. Orphanet J Rare Dis (2013) 0.87

Implication of MYH in colorectal polyposis. Ann Surg (2006) 0.87

Duodenal carcinoma in MUTYH-associated polyposis. J Clin Pathol (2006) 0.86

Early postoperative and long-term oncological outcomes of laparoscopic treatment for patients with familial adenomatous polyposis. J Korean Surg Soc (2012) 0.86

Familial adenomatous polyposis of the colon. Hered Cancer Clin Pract (2013) 0.86

Precancerous lesions in colorectal cancer. Gastroenterol Res Pract (2013) 0.86

Patient preferences regarding recontact by cancer genetics clinicians. Fam Cancer (2007) 0.86

Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin. Fam Cancer (2007) 0.85

A comparison of the phenotype and genotype in adenomatous polyposis patients with and without a family history. Fam Cancer (2005) 0.85

Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: case report. BMC Med Genet (2011) 0.85

MYH, OGG1, MTH1, and APC alterations involved in the colorectal tumorigenesis of Korean patients with multiple adenomas. Virchows Arch (2007) 0.84

A haplotype variation affecting the mitochondrial transportation of hMYH protein could be a risk factor for colorectal cancer in Chinese. BMC Cancer (2008) 0.84

Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk. Dis Colon Rectum (2008) 0.83

Multiple adenomatous duodenal polyposis. Case Rep Gastrointest Med (2013) 0.83

Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer (2016) 0.83

Meta-analysis of mismatch repair polymorphisms within the cogent consortium for colorectal cancer susceptibility. PLoS One (2013) 0.82

Analysis of inherited MYH/(MutYH) mutations in British Asian patients with colorectal cancer. Gut (2007) 0.82

MUTYH-associated colorectal cancer and adenomatous polyposis. Surg Today (2013) 0.82

Analysis of rare APC variants at the mRNA level: six pathogenic mutations and literature review. J Mol Diagn (2009) 0.82

Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genet Med (2015) 0.81

MYH mutations are rare in prostate cancer. J Cancer Res Clin Oncol (2007) 0.81

MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. Eur J Hum Genet (2013) 0.81

Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. Tech Coloproctol (2012) 0.80

Mechanisms of inherited cancer susceptibility. J Zhejiang Univ Sci B (2008) 0.80

The role of MutY homolog (Myh1) in controlling the histone deacetylase Hst4 in the fission yeast Schizosaccharomyces pombe. J Mol Biol (2010) 0.80

Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes. J Pathol (2015) 0.80

Identification of patients at risk for hereditary colorectal cancer. Clin Colon Rectal Surg (2012) 0.79

The history of familial adenomatous polyposis. Fam Cancer (2006) 0.79

Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary. Fam Cancer (2016) 0.79

Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas. Neuro Oncol (2016) 0.78

Tissue Metabonomic Phenotyping for Diagnosis and Prognosis of Human Colorectal Cancer. Sci Rep (2016) 0.78

Diagnostic Approach to Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg (2015) 0.78

MUTYH-associated polyposis (MAP), the syndrome implicating base excision repair in inherited predisposition to colorectal tumors. Front Oncol (2012) 0.78

Familial colorectal cancer: a genetics treasure trove for medical discovery. JAMA (2008) 0.78

Germline MUTYH gene mutations are not frequently found in unselected patients with papillary breast carcinoma. Hered Cancer Clin Pract (2014) 0.77

Familial adenomatous polyposis and MYH. Lancet (2003) 0.77

Adenoma development in a patient with MUTYH-associated polyposis (MAP): new insights into the natural course of polyp development. Dig Dis Sci (2009) 0.77

Impaired suppressive activities of human MUTYH variant proteins against oxidative mutagenesis. World J Gastroenterol (2012) 0.77

Base excision repair and the role of MUTYH. Hered Cancer Clin Pract (2007) 0.77

Variation of a variation: case report of attenuated familial adenomatous polyposis. HPB (Oxford) (2006) 0.77

Interaction of apurinic/apyrimidinic endonuclease 2 (Apn2) with Myh1 DNA glycosylase in fission yeast. DNA Repair (Amst) (2014) 0.77

High prevalence of the c.1227_1228dup (p.Glu410GlyfsX43) mutation in Tunisian families affected with MUTYH-associated-polyposis. Fam Cancer (2012) 0.77

Papillary thyroid cancer in a patient with MUTYH-associated polyposis (MAP). Fam Cancer (2010) 0.77

The genomics of colorectal cancer: state of the art. Curr Genomics (2008) 0.76

Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations. BMC Med Genet (2007) 0.76

Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway. Cancer Sci (2016) 0.75

Lower gastrointestinal tract cancer predisposition syndromes. Hematol Oncol Clin North Am (2010) 0.75

Type and frequency of MUTYH variants in Italian patients with suspected MAP: a retrospective multicenter study. J Hum Genet (2016) 0.75

A complex rearrangement in the APC gene uncovered by multiplex ligation-dependent probe amplification. J Mol Diagn (2007) 0.75

Familial adenomatous polyposis in China. Oncol Lett (2016) 0.75

Inherited colorectal cancer syndromes. Clin Colon Rectal Surg (2005) 0.75

Gastrointestinal tract cancers: Genetics, heritability and germ line mutations. Oncol Lett (2017) 0.75

A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocr Relat Cancer (2017) 0.75

Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management. Am J Gastroenterol (2017) 0.75

[Colorectal polyposis syndrome: a guide to diagnosis]. Pathologe (2011) 0.75

Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer. Fam Cancer (2017) 0.75

Articles by these authors

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72

Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30

Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet (2002) 7.00

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67

A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet (2011) 5.29

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20

Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99

Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76

Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol (2009) 3.60

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54

Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res (2008) 3.49

MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37

Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19

The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet (2006) 3.19

TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet (2011) 3.06

An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05

PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet (2006) 2.97

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst (2013) 2.93

Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst (2008) 2.89

Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87

Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat (2010) 2.75

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70

Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut (2011) 2.68

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66

Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet (2005) 2.62

Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol (2010) 2.60

Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-->T:A mutations. Hum Mol Genet (2002) 2.48

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39

A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst (2003) 2.25

Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25

Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet (2008) 2.24

Whole-exome-sequencing-based discovery of human FADD deficiency. Am J Hum Genet (2010) 2.17

Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann Neurol (2007) 2.13

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. J Natl Cancer Inst (2013) 2.13

SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res (2002) 2.09

Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet (2004) 2.04

Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet (2010) 2.00

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99

Mutations of the catalytic subunit of RAB3GAP cause Warburg Micro syndrome. Nat Genet (2005) 1.98

The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res (2014) 1.97

Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol (2012) 1.90

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90

Protein-truncating mutations in ASPM cause variable reduction in brain size. Am J Hum Genet (2003) 1.89

Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88

An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotype. Hum Mol Genet (2003) 1.85

Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer (2007) 1.84

Impact of wound edge protection devices on surgical site infection after laparotomy: multicentre randomised controlled trial (ROSSINI Trial). BMJ (2013) 1.83

Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res (2006) 1.77

Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet (2012) 1.76

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73

Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72